Please assess the completion status of the following clinical trial:

Trial Title: Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed PC with malignant ascites.~* Karnofsky Performance Status (KPS) score ≥60%.~* Normal function of bone marrow.~* Predicted survival time \>1 month.~* Written informed consent.~Exclusion Criteria:~* Surgery within 3 weeks or not full recovery of postoperative suture.~* Active bleeding or vascular occlusion in the mEHT treatment area.~* Emotional instability.~* Impossibility to place the patient into the mEHT machine.~* Metallic implants or replacements in the treatment area.~* Electronic implanted devices anywhere.~* Missing or damaged heat-sense nerves or other field-sensitive issues in the treatment area.~* Very low white blood cell count (\<1.5×10(9)/L), agranulocytosis (\<0.5×10(9)/L) or severe anemia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Study Group (Type: EXPERIMENTAL): Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
- Control Group (Type: ACTIVE_COMPARATOR): IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.

Based on this trial design, predict the completion outcome and termination type (if applicable).